Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $413000.0.

  • Bio-Techne's Exchange Rate Effect rose 10755.3% to $413000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $11.5 million, marking a year-over-year increase of 34438.85%. This contributed to the annual value of $11.9 million for FY2025, which is 61123.02% up from last year.
  • According to the latest figures from Q4 2025, Bio-Techne's Exchange Rate Effect is $413000.0, which was up 10755.3% from -$1.2 million recorded in Q3 2025.
  • Bio-Techne's 5-year Exchange Rate Effect high stood at $13.4 million for Q2 2025, and its period low was -$11.9 million during Q3 2022.
  • Over the past 5 years, Bio-Techne's median Exchange Rate Effect value was -$465500.0 (recorded in 2021), while the average stood at -$282950.0.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first tumbled by 454866.67% in 2022, then skyrocketed by 56918.29% in 2024.
  • Bio-Techne's Exchange Rate Effect (Quarter) stood at $3.1 million in 2021, then soared by 138.86% to $7.3 million in 2022, then tumbled by 53.4% to $3.4 million in 2023, then plummeted by 259.74% to -$5.5 million in 2024, then skyrocketed by 107.55% to $413000.0 in 2025.
  • Its last three reported values are $413000.0 in Q4 2025, -$1.2 million for Q3 2025, and $13.4 million during Q2 2025.